Advertisement

Topics

[Articles] Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Typhi: a randomised controlled, phase 2b trial

21:07 EDT 28 Sep 2017 | The Lancet

Vi-TT is a highly immunogenic vaccine that significantly reduces typhoid fever cases when assessed using a stringent controlled model of typhoid infection. Vi-TT use has the potential to reduce both the burden of typhoid fever and associated health inequality.

Original Article: [Articles] Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Typhi: a randomised controlled, phase 2b trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Typhi: a randomised controlled, phase 2b trial"

Quick Search
Advertisement
 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Typbar-TCV Typhoid Conjugate Vaccine
Typbar-TCV™, world's first clinically proven typhoid conjugate vaccine for infants 6 months & older and Adults. The new vaccine brings hope to millions of adults and infants older than 6 months, by protecting against typhoid fever caused...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...